Stryker receives FDA clearance for Incompass Total Ankle System
PORTAGE, Mich.--(BUSINESS WIRE)--Stryker (NYSE:SYK), a global leader in medical technologies, announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the Incompass® Total Ankle System, an implant intended for patients with ankle joints damaged by severe rheumatoid, post-traumatic, or degenerative arthritis. This new platform integrates the innovative technologies of Stryker's Inbone® and Infinity® systems into a single, comprehensive solution for total ankle replacement.
'Incompass reflects our commitment to redefining what's possible in total ankle replacement,' said Adam Jacobs, vice president and general manager of Stryker's Foot & Ankle business. 'By building on decades of clinical experience and leveraging extensive data insights, we're setting a new standard—one that empowers surgeons to deliver more personalized care with greater efficiency and confidence.'
Incompass incorporates Adaptis® Boney Ingrowth Technology and redesigned instrumentation to support long-term fixation, surgical flexibility and streamlined workflow. Developed to address key challenges in total ankle replacement, including intraoperative adaptability and procedural efficiency, the system is informed by data from more than 85,000 CT scans¹ and 100,000 clinical cases.¹ It also offers a broad range of implant and instrumentation options to support patient-specific care.
Built using the Stryker Orthopaedic Modeling & Analytics (SOMA) platform in combination with arthritic ankle scans from the company's Prophecy Surgical Planning System, Incompass provides a continuum of implant and instrument options designed to accommodate both surgeon preference and patient anatomy. System enhancements include a redesigned alignment system for greater control across multiple planes, updated implant holders and trial tools for improved handling, and instrumentation refinements designed to reduce surgical steps and set up time.
About Stryker
Stryker is a global leader in medical technologies and, together with its customers, is driven to make healthcare better. The company offers innovative products and services in MedSurg, Neurotechnology, and Orthopaedics that help improve patient and healthcare outcomes. Alongside its customers around the world, Stryker impacts more than 150 million patients annually. More information is available at www.stryker.com.
Copyright © 2025 Stryker
Content ID: FA-INCO-PRESS-2016296
References:
1. Based on internal data as of 5/1/2025.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 minutes ago
- Yahoo
Walmart's (NYSE:WMT) Dividend Will Be $0.235
Walmart Inc.'s (NYSE:WMT) investors are due to receive a payment of $0.235 per share on 2nd of September. Even though the dividend went up, the yield is still quite low at only 1.0%. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. If it is predictable over a long period, even low dividend yields can be attractive. Before making this announcement, Walmart was easily earning enough to cover the dividend. This means that most of its earnings are being retained to grow the business. Over the next year, EPS is forecast to expand by 44.4%. Assuming the dividend continues along recent trends, we think the payout ratio could be 27% by next year, which is in a pretty sustainable range. View our latest analysis for Walmart The company has an extended history of paying stable dividends. The annual payment during the last 10 years was $0.653 in 2015, and the most recent fiscal year payment was $0.94. This means that it has been growing its distributions at 3.7% per annum over that time. Dividends have grown relatively slowly, which is not great, but some investors may value the relative consistency of the dividend. Some investors will be chomping at the bit to buy some of the company's stock based on its dividend history. Walmart has impressed us by growing EPS at 6.0% per year over the past five years. A low payout ratio and decent growth suggests that the company is reinvesting well, and it also has plenty of room to increase the dividend over time. In summary, it is always positive to see the dividend being increased, and we are particularly pleased with its overall sustainability. Distributions are quite easily covered by earnings, which are also being converted to cash flows. All in all, this checks a lot of the boxes we look for when choosing an income stock. Investors generally tend to favour companies with a consistent, stable dividend policy as opposed to those operating an irregular one. Still, investors need to consider a host of other factors, apart from dividend payments, when analysing a company. For instance, we've picked out 2 warning signs for Walmart that investors should take into consideration. Looking for more high-yielding dividend ideas? Try our collection of strong dividend payers. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Yahoo
16 minutes ago
- Yahoo
ServiceNow (NOW) Just Got a Price Target Boost—Here's What's Behind It
ServiceNow, Inc. (NYSE:NOW) is one of the 10 AI Stocks Making Waves on Wall Street. On June 25, D.A. Davidson initiated the stock as 'Buy'. The firm believes that the company is 'best-of-breed.' 'We are initiating coverage of NOW with a BUY rating and a $1,150 price target. ServiceNow has been a market leading business automation provider for over two decades now.' The firm further stated that the company is "in the early stages of disrupting the CRM market, which is undergoing a once in a generation shift due to AI." Its business moat comes from "a combination of its platform architecture, deep enterprise integration, high switching costs, a strong brand, and vertical specialization." That said, analysts at DA Davidson expect ServiceNow to leverage its AI capabilities and best-of-breed platform to gain additional market share beyond the traditional IT service management (ITSM). ServiceNow, Inc. (NYSE:NOW) is a technology company that offers a cloud-based software platform for automating business workflows within an enterprise. While we acknowledge the potential of NOW as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 AI Stocks in the Spotlight and . Disclosure: None.
Yahoo
21 minutes ago
- Yahoo
Lantheus Joins FIBRE Consortium with Pfizer, Lumina to Revolutionize Fibrotic Disease Treatment
Lantheus Holdings Inc. (NASDAQ:LNTH) is one of the most undervalued US stocks according to analysts. On June 20, Lantheus Holdings announced its participation in the newly launched FIBRE Consortium, which is a collaborative initiative with Pfizer Inc. (NYSE:PFE) and Lumina Pharmaceuticals. The consortium's primary goal is to revolutionize the treatment of fibrotic diseases by using advanced imaging biomarkers. The FIBRE (Fibrosis Imaging Biomarker Research & Evaluation) Consortium aims to accelerate biomarker validation and reduce the costs of clinical trials for fibrotic diseases through innovative imaging technologies. Lantheus's contribution includes supplying LNTH-1363S, which is a PET tracer targeting Fibroblast Activation Protein/FAP. FAP is a protein expressed exclusively by activated fibroblasts. A medical professional performing a pulmonary function assessment on a patient. This biomarker, along with Lumina's [⁶⁸Ga]CBP8 PET/MRI tracer for Collagen Type I, will enable the quantification of fibrosis burden and treatment response within weeks, and potentially reduce trial durations by 60% and costs by ~$400 million. Initial studies will focus on Metabolic Dysfunction-Associated Steatohepatitis/MASH, with potential expansion into other fibrotic conditions. Lantheus Holdings Inc. (NASDAQ:LNTH) develops, manufactures, and commercializes diagnostic and therapeutic products that assist in the diagnosis and treatment of heart, cancer, and other diseases. While we acknowledge the potential of LNTH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
